藍耿欣醫師詳細介紹

日本東京大學醫學院博士

國立陽明大學醫學系學士

-迄今台北榮民總醫院胃腸肝膽科主治醫師

-迄今國立陽明大學醫學系教授

-日本廣島大學醫學院分子病態制御內科學胃腸部門研究員

-美國國家衛生研究院肝病研究室研究員

-台北榮民總醫院胃腸科總醫師

-台北榮民總醫院內科部住院醫師

慢性B型、C型肝炎之治療

肝硬化及肝癌之診斷及治療

肝膽胃腸疾病

腹部超音波及消化道內視鏡診斷及治療

內科醫學會

消化系醫學會

消化系內視鏡醫學會

英語

國語

日語

Lee WP, Lan KL, Liao SX, Huang YH, Hou MC, Lan KH*. Inhibitory Effects of Amentoflavone and Orobol on Daclatasvir-Induced Resistance-Associated Variants of Hepatitis C Virus. Am J Chin Med. 2018; 46:835-852. (*Corresponding author)

Lee WP, Lan KL, Liao SX, Huang YH, Hou MC, Lan KH*. The Antiviral Effect of Saikosaponin B2 in combination with Daclatasvir on NS5A Resistance-associated Substitutions of Hepatitis C Virus. J Chin Med Assoc 2019; 82: 368-374. (*Corresponding author)

Wang YK, Lee WP, Wang, YW, Huang YH, Hou MC, Chang YL, and Lan KH*. Precipitating factors causing hyperbilirubinemia in chronic hepatitis C treated with paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Chin Med Assoc 2020 Dec;83(12):1071-1078. (*Corresponding author)

Wang YW, Lee WP, Huang, YH, Hou MC, Lan KH*. Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis. BMC Infect Dis. 2021 Sep 21;21(1):984. (*Corresponding author)

Wang, YK., Wang, YW., Lu, CL, Huang, YH., Hou, MC., Lee, WP*., Lan, KH*. Sofosbuvir-based direct-acting antivirals and changes in cholesterol and low density lipoprotein-cholesterol. Sci Rep. 2022 Jun 15; 12(1):9942. (*Corresponding author).